Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 12/2015

Open Access 01-11-2015 | Breast Oncology

Three-Dimensional Breast Radiotherapy and the Elective Radiation Dose at the Sentinel Lymph Node Site in Breast Cancer

Authors: Lori M. van Roozendaal, MD, Robert-Jan Schipper, MD, Leonie H. M. Smit, MD, PhD, Boudewijn T. Brans, MD, PhD, Regina G. H. Beets-Tan, MD, PhD, Marc B. I. Lobbes, MD, PhD, Liesbeth J. Boersma, MD, PhD, Marjolein L. Smidt, MD, PhD

Published in: Annals of Surgical Oncology | Issue 12/2015

Login to get access

Abstract

Background

Several trials are presently randomizing clinically node-negative breast cancer patients treated with breast-conserving therapy (BCT) to sentinel lymph node biopsy (SLNB) or watchful waiting. We aimed to investigate the elective radiation dose at the sentinel lymph node (SLN) site while evaluating two techniques for SLN localization, in breast cancer patients treated with lumpectomy and three-dimensional (3D) whole-breast radiotherapy.

Methods

The SLN site of consecutive Tis-2N0 breast cancer patients undergoing lumpectomy and forward intensity-modulated whole-breast radiotherapy was determined by the location of the hotspot on preoperative single-photon emission computed tomography (SPECT)/computed tomography (CT) and by a surgical clip placed at the removed SLN(s) during SLNB. The radiation dose at the SLN site was subsequently determined on the postoperative radiotherapy planning CT. An elective radiation dose to the SLN site was defined as at least 95 % of the breast dose.

Results

Of the 42 included patients, the mean percentage of the breast dose on the SLN site was 90 % (standard deviation 26, range 7–132, median 99), with a non-significant difference between the two techniques (surgical clip or SPECT/CT) (p = 0.608). In 32/42 patients (76 %) the SLN site received an elective radiation dose.

Conclusions

A surgical clip placed at the removed SLN(s) during SLNB proved to be an adequate method of determining the radiation dose at the SLN site when compared with using SPECT/CT. With the use of 3D radiotherapy, the site of the SLN is treated with an elective radiation dose in the majority of patients who are treated with BCT.
Literature
1.
Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347(16):1233–41.CrossRefPubMed
2.
Early Breast Cancer Trialists’ Collaborative Group, Darby S, McGale P, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378(9804):1707–16.CrossRef
3.
van Wely BJ, Teerenstra S, Schinagl DA, Aufenacker TJ, de Wilt JH, Strobbe LJ. Systematic review of the effect of external beam radiation therapy to the breast on axillary recurrence after negative sentinel lymph node biopsy. Br J Surg. 2011;98(3):326–33.CrossRefPubMed
4.
Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305(6):569–75.CrossRefPubMed
5.
Giuliano AE, McCall L, Beitsch P, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg. 2010;252(3):426–32.PubMed
6.
Alco G, Dincer M. Are the standard tangential breast irradiation fields used in the ACOSOG Z0011 trial really covering the entire axilla? Ann Surg. 2013;257(1):e1.CrossRefPubMed
7.
Belkacemi Y, Allab-Pan Q, Bigorie V, et al. The standard tangential fields used for breast irradiation do not allow optimal coverage and dose distribution in axillary levels I–II and the sentinel node area. Ann Oncol. 2013;24(8):2023–2028.CrossRefPubMed
8.
Reznik J, Cicchetti MG, Degaspe B, Fitzgerald TJ. Analysis of axillary coverage during tangential radiation therapy to the breast. Int J Radiat Oncol Biol Phys. 2005;61(1):163–8.CrossRefPubMed
9.
Reed DR, Lindsley SK, Mann GN, et al. Axillary lymph node dose with tangential breast irradiation. Int J Radiat Oncol Biol Phys. 2005;61(2):358–64.CrossRefPubMed
10.
Kataria T, Bisht SS, Gupta D, et al. Incidental radiation to axilla in early breast cancer treated with intensity modulated tangents and comparison with conventional and 3D conformal tangents. Breast. 2013;22(6):1125–9.CrossRefPubMed
11.
van Roozendaal LM, de Wilt JHW, Smidt ML. Clinically node negative breast cancer patients undergoing breast conserving therapy: follow-up versus sentinel lymph node biopsy. 35th Annual San Antonio Breast Cancer Symposium; 4–8 Dec 2012: San Antonio (TX).
12.
Gentilini O, Veronesi U. Abandoning sentinel lymph node biopsy in early breast cancer? A new trial in progress at the European Institute of Oncology of Milan (SOUND: Sentinel node vs Observation after axillary UltraSouND). Breast. 2012;21(5):678–81.CrossRefPubMed
13.
Nadeem RM. The feasibility of SNIPE trial; sentinel lymph node biopsy vs. no-SLNB in patients with early breast cancer. Cancer Res. 2013;73(24 Suppl):P1–01.
14.
Rabinovitch R, Ballonoff A, Newman F, Finlayson C. Evaluation of breast sentinel lymph node coverage by standard radiation therapy fields. Int J Radiat Oncol Biol Phys. 2008;70(5):1468–71.CrossRefPubMed
15.
Schlembach PJ, Buchholz TA, Ross MI, et al. Relationship of sentinel and axillary level I–II lymph nodes to tangential fields used in breast irradiation. Int J Radiat Oncol Biol Phys. 2001;51(3):671–8.CrossRefPubMed
16.
Chung MA, DiPetrillo T, Hernandez S, Masko G, Wazer D, Cady B. Treatment of the axilla by tangential breast radiotherapy in women with invasive breast cancer. Am J Surg. 2002;184(5):401–2.CrossRefPubMed
17.
Boersma LJ, Janssen T, Elkhuizen PH, et al. Reducing interobserver variation of boost-CTV delineation in breast conserving radiation therapy using a pre-operative CT and delineation guidelines. Radiother Oncol. 2012;103(2):178–82.CrossRefPubMed
18.
Peulen H, Hanbeukers B, Boersma L, et al. Forward intensity-modulated radiotherapy planning in breast cancer to improve dose homogeneity: feasibility of class solutions. Int J Radiat Oncol Biol Phys. 2012;82(1):394–400.CrossRefPubMed
19.
Hurkmans CW, Borger JH, Bos LJ, et al. Cardiac and lung complication probabilities after breast cancer irradiation. Radiother Oncol. 2000;55(2):145–51.CrossRefPubMed
20.
Seo Y, Mari C, Hasegawa BH. Technological development and advances in single-photon emission computed tomography/computed tomography. Semin Nucl Med. 2008;38(3):177–98.PubMedCentralCrossRefPubMed
21.
Bentzen SM, Dische S. Morbidity related to axillary irradiation in the treatment of breast cancer. Acta Oncol. 2000;39(3):337–47.CrossRefPubMed
22.
Haffty BG, Hunt KK, Harris JR, Buchholz TA. Positive sentinel nodes without axillary dissection: implications for the radiation oncologist. J Clin Oncol. 2011;29(34):4479–81.CrossRefPubMed
23.
Uren RF, Howman-Giles R, Chung DK, et al. SPECT/CT scans allow precise anatomical location of sentinel lymph nodes in breast cancer and redefine lymphatic drainage from the breast to the axilla. Breast. 2012;21(4):480–6.CrossRefPubMed
24.
Hatfield P, Cooper R, Sebag-Montefiore D. Involved-field, low-dose chemoradiotherapy for early-stage anal carcinoma. Int J Radiat Oncol Biol Phys. 2008;70(2):419–24.CrossRefPubMed
25.
Marks LB. A standard dose of radiation for “microscopic disease” is not appropriate. Cancer. 1990;66(12):2498–2502.CrossRefPubMed
26.
Withers HR, Suwinski R. Radiation dose response for subclinical metastases. Semin Radiat Oncol. 1998;8(3):224–8.CrossRefPubMed
Metadata
Title
Three-Dimensional Breast Radiotherapy and the Elective Radiation Dose at the Sentinel Lymph Node Site in Breast Cancer
Authors
Lori M. van Roozendaal, MD
Robert-Jan Schipper, MD
Leonie H. M. Smit, MD, PhD
Boudewijn T. Brans, MD, PhD
Regina G. H. Beets-Tan, MD, PhD
Marc B. I. Lobbes, MD, PhD
Liesbeth J. Boersma, MD, PhD
Marjolein L. Smidt, MD, PhD
Publication date
01-11-2015
Publisher
Springer US
Published in
Annals of Surgical Oncology / Issue 12/2015
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-015-4413-7

Other articles of this Issue 12/2015

Annals of Surgical Oncology 12/2015 Go to the issue

Colorectal Cancer

Validation of the Memorial Sloan-Kettering Cancer Center Nomogram to Predict Overall Survival After Curative Colectomy in a Chinese Colon Cancer Population

Gastrointestinal Oncology

Circulating Tumor Cells as an Independent Predictor of Survival in Advanced Gastric Cancer

Breast Oncology

Perceptions of Contralateral Breast Cancer Risk: A Prospective, Longitudinal Study

Bone and Soft Tissue Sarcomas

Radiation-Associated Undifferentiated Pleomorphic Sarcoma is Associated with Worse Clinical Outcomes than Sporadic Lesions

Hepatobiliary Tumors

The Impact of Surgical Margin Status on Long-Term Outcome After Resection for Intrahepatic Cholangiocarcinoma

Endocrine Tumors

Wide Inter-institutional Variation in Performance of a Molecular Classifier for Indeterminate Thyroid Nodules